What is GALAXY?
GALAXY is a H2020 project that aims to optimize personalized healthcare for patients with liver disease,
by stratifying individuals who would benefit from targeted healthcare efforts versus those who would not,
and thus to reduce the economic burden for health care systems and to improve health outcome for the patients.
GALAXY has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 668031
Multinational collaboration establish common cut-offs for liver stiffness measurements
Finally, researchers have agreed on the interpretation of liver stiffness measurements. There has long been disagreement about which cut-off values to use for transient elastography (FibroScan). With the use of GALAXY data, a multinational collaboration has now established cut-off values to rule in and rule out compensated advanced chronic liver disease across the four major liver disease etiologies.
Inclusion of patients
Inclusion of patients concluded in the fourth GALAXY study
55 patients with alcoholic liver disease are now included in the SYN-ALD a randomized controlled trial in GALAXY.
GALAXY part of multi-centre study published in AP&T
New study shows that digital assistance improves physician’s accuracy to predict who will develop complication to cirrhosis and die from alcohol-related liver disease.
Five abstracts from the GALAXY project was presented on 27-29 August at the Digital International Liver Congress 2020
GALAXY Clinical Trials
136 ALD patients included in the Rifaximin trial
In May 2020 an important milestone in the Rifaximin study was reached, since the last of 136 participants was included.
GALAXY Steering Committee Meeting
The GALAXY partners met in Copenhagen for Steering Committee Meeting
Best of the Liver Meeting 2019
GALAXY had two oral presentations at the Liver Meeting 2019 - one was selected as part of Best of Liver Meeting 2019
GALAXY Advisory Board
GALAXY hosted meeting at AASLD in Boston